Hydrogen-Generating Microalgae Shows Promise for Cancer Treatment
- Authors
- Shuiling Chen, Ming Li, Yu Zhang, Yushu Dong, Jinying Wu, Lixiang Li, Xing Guo, Xia Liu, Jianwen Hou, Shaobing Zhou
- Journal
- Science Advances
- Year
- 2025
- DOI
- 10.1126/sciadv.adw4212
- Study Type
- Mouse
- Outcome
- Positive
- Peer Reviewed
- Yes
- Country
- China
- Health Condition
- Cancer
- Body System
- Immune System
TL;DR
Photoactivated microalgae nanoplatform (PCC@AuNP) boosts antitumor immunity via hydrogen-induced cell death and tumor microenvironment remodeling.
Key Finding
Photoactivatable nanoengineered microalgae generated hydrogen gas that induced cancer cell death while simultaneously reducing the tumor's ability to suppress immune responses, effectively treating both primary tumors and distant metastases in mice.
Summary
Researchers developed a treatment using specially engineered microalgae (tiny algae cells) combined with gold nanoparticles that can be activated by light. When activated, this treatment produces hydrogen gas, which triggers cancer cells to die in a way that alerts the immune system. At the same time, it reduces the protective shield that tumors use to hide from the immune system. In mouse studies, this treatment eliminated primary tumors and prevented distant cancer spread without harming healthy tissue.
Practical Takeaway
This is early-stage research in mice only, not yet tested in humans. While the results are promising for a new type of cancer immunotherapy using hydrogen gas, it represents a laboratory proof-of-concept rather than a treatment available to patients. Much more research would be needed before this approach could be considered for human use.
Abstract
Limited tumor immunogenicity and the profoundly immunosuppressive tumor microenvironment (TME) pose major challenges to effective cancer immunotherapy. Herein, we present a photoactivatable immunostimulator based on nanoengineered microalgae (PCC@AuNP) to simultaneously enhance tumor immunogenicity and remodel the TME. Mechanistically, photocatalytically generated hydrogen induces robust immunogenic cell death by triggering severe endoplasmic reticulum stress and mitochondrial dysfunction. Concurrently, photosynthetic oxygen production and photocatalytic lactic acid depletion collaboratively alleviate immunosuppression within the TME, thereby enhancing cytotoxic T lymphocyte activity by reducing the infiltration of immunosuppressive cells and promoting the repolarization of tumor-associated macrophages from the M2 to the M1 phenotype. In vivo studies demonstrate that PCC@AuNP not only eradicates primary tumors but also elicits potent systemic antitumor immunity against distant lesions, without observable toxicity to healthy tissues. Collectively, this innovative PCC@AuNP platform offers a safe and effective therapeutic strategy, heralding a pioneering era of cascade-augmented gas-driven cancer immunotherapy with superior precision and biosafety.